Cargando…
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impac...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564579/ https://www.ncbi.nlm.nih.gov/pubmed/32764508 http://dx.doi.org/10.3390/vaccines8030442 |
_version_ | 1783595747014344704 |
---|---|
author | Leal, Lorna Fehér, Csaba Richart, Valèria Torres, Berta García, Felipe |
author_facet | Leal, Lorna Fehér, Csaba Richart, Valèria Torres, Berta García, Felipe |
author_sort | Leal, Lorna |
collection | PubMed |
description | A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials. |
format | Online Article Text |
id | pubmed-7564579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75645792020-10-29 Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response Leal, Lorna Fehér, Csaba Richart, Valèria Torres, Berta García, Felipe Vaccines (Basel) Review A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials. MDPI 2020-08-05 /pmc/articles/PMC7564579/ /pubmed/32764508 http://dx.doi.org/10.3390/vaccines8030442 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Leal, Lorna Fehér, Csaba Richart, Valèria Torres, Berta García, Felipe Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title_full | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title_fullStr | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title_full_unstemmed | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title_short | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
title_sort | antiretroviral therapy interruption (ati) in hiv-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564579/ https://www.ncbi.nlm.nih.gov/pubmed/32764508 http://dx.doi.org/10.3390/vaccines8030442 |
work_keys_str_mv | AT leallorna antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT fehercsaba antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT richartvaleria antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT torresberta antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT garciafelipe antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse |